By HFT Staff

Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center (BIDMC) reached a major milestone in their Cancer Collaboration, officially initiating the construction process for the region’s only dedicated adult inpatient cancer hospital. Work begins with the deconstruction of the former Joslin Diabetes Center building at One Joslin Place. 

Over the past two years, Joslin Diabetes Center relocated its clinics, clinical research center and research laboratories to sites on BIDMC’s East Campus and the Center for Life Science to enable deconstruction of its former building. 

The new 300-bed cancer hospital, first announced in September 2023, will deliver more specialized care and improved outcomes for patients. Spanning 450,000 square feet across 10 inpatient floors, the facility is designed to provide a seamless, oncology-focused patient experience. Built to evolve with rapid advances in cancer treatment, the hospital will expand capacity, address the growing incidence of cancer, and ensure timely access to world-class care. Construction will continue through the hospital’s planned opening in 2031. 

The facility, situated in the Longwood Medical Area, will offer an enhanced patient experience designed exclusively around the needs of oncology patients. Supported by a clinical collaboration among Dana-Farber, BIDMC, and Harvard Medical Faculty Physicians (HMFP), BIDMC’s affiliated physician organization, the interlocking campus will connect Dana-Farber and BIDMC — enabling integrated, multidisciplinary care across the full continuum of the patient journey.